Pliant Therapeutics Statistics
Total Valuation
PLRX has a market cap or net worth of $83.85 million. The enterprise value is -$209.50 million.
Important Dates
The last earnings date was Monday, March 3, 2025, after market close.
| Earnings Date | Mar 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
PLRX has 61.24 million shares outstanding. The number of shares has increased by 3.10% in one year.
| Current Share Class | 61.24M |
| Shares Outstanding | 61.24M |
| Shares Change (YoY) | +3.10% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 3.05% |
| Owned by Institutions (%) | 94.63% |
| Float | 50.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.29 |
| P/TBV Ratio | 0.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.91, with a Debt / Equity ratio of 0.20.
| Current Ratio | 10.91 |
| Quick Ratio | 10.78 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -75.52 |
Financial Efficiency
Return on equity (ROE) is -54.09% and return on invested capital (ROIC) is -33.61%.
| Return on Equity (ROE) | -54.09% |
| Return on Assets (ROA) | -31.40% |
| Return on Invested Capital (ROIC) | -33.61% |
| Return on Capital Employed (ROCE) | -62.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.23M |
| Employee Count | 171 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.90% in the last 52 weeks. The beta is 1.19, so PLRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -89.90% |
| 50-Day Moving Average | 4.99 |
| 200-Day Moving Average | 10.91 |
| Relative Strength Index (RSI) | 26.83 |
| Average Volume (20 Days) | 3,387,310 |
Short Selling Information
The latest short interest is 3.98 million, so 6.50% of the outstanding shares have been sold short.
| Short Interest | 3.98M |
| Short Previous Month | 3.29M |
| Short % of Shares Out | 6.50% |
| Short % of Float | 7.92% |
| Short Ratio (days to cover) | 1.07 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -228.37M |
| Pretax Income | n/a |
| Net Income | -210.30M |
| EBITDA | -226.24M |
| EBIT | -228.37M |
| Earnings Per Share (EPS) | -$3.47 |
Full Income StatementBalance Sheet
The company has $355.72 million in cash and $60.19 million in debt, giving a net cash position of $295.53 million or $4.83 per share.
| Cash & Cash Equivalents | 355.72M |
| Total Debt | 60.19M |
| Net Cash | 295.53M |
| Net Cash Per Share | $4.83 |
| Equity (Book Value) | 304.08M |
| Book Value Per Share | 5.00 |
| Working Capital | 329.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$155.50 million and capital expenditures -$3.85 million, giving a free cash flow of -$159.35 million.
| Operating Cash Flow | -155.50M |
| Capital Expenditures | -3.85M |
| Free Cash Flow | -159.35M |
| FCF Per Share | -$2.60 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |